JP5892612B2 - 疾患の処置に有用な新規のｍｅｋ阻害剤 - Google Patents

疾患の処置に有用な新規のｍｅｋ阻害剤 Download PDF

Info

Publication number
JP5892612B2
JP5892612B2 JP2012534327A JP2012534327A JP5892612B2 JP 5892612 B2 JP5892612 B2 JP 5892612B2 JP 2012534327 A JP2012534327 A JP 2012534327A JP 2012534327 A JP2012534327 A JP 2012534327A JP 5892612 B2 JP5892612 B2 JP 5892612B2
Authority
JP
Japan
Prior art keywords
compound
cancer
mmol
solution
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012534327A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013507453A (ja
JP2013507453A5 (https=
Inventor
アール． キレ，ウダイ
アール． キレ，ウダイ
デヴィチャンド コーディア，マヘンドラ
デヴィチャンド コーディア，マヘンドラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allomek Therapeutics LLC
Original Assignee
Allomek Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allomek Therapeutics LLC filed Critical Allomek Therapeutics LLC
Publication of JP2013507453A publication Critical patent/JP2013507453A/ja
Publication of JP2013507453A5 publication Critical patent/JP2013507453A5/ja
Application granted granted Critical
Publication of JP5892612B2 publication Critical patent/JP5892612B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/08—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2012534327A 2009-10-13 2010-10-13 疾患の処置に有用な新規のｍｅｋ阻害剤 Active JP5892612B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25093609P 2009-10-13 2009-10-13
US61/250,936 2009-10-13
PCT/US2010/052514 WO2011047055A2 (en) 2009-10-13 2010-10-13 Novel mek inhibitors, useful in the treatment of diseases

Publications (3)

Publication Number Publication Date
JP2013507453A JP2013507453A (ja) 2013-03-04
JP2013507453A5 JP2013507453A5 (https=) 2013-11-28
JP5892612B2 true JP5892612B2 (ja) 2016-03-23

Family

ID=43876849

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012534327A Active JP5892612B2 (ja) 2009-10-13 2010-10-13 疾患の処置に有用な新規のｍｅｋ阻害剤

Country Status (10)

Country Link
US (1) US9034861B2 (https=)
EP (1) EP2488507B1 (https=)
JP (1) JP5892612B2 (https=)
KR (1) KR20120094165A (https=)
CN (1) CN102666512B (https=)
AU (1) AU2010306830C1 (https=)
BR (1) BR112012008599A2 (https=)
CA (1) CA2814617C (https=)
ES (1) ES2534358T3 (https=)
WO (1) WO2011047055A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190008859A1 (en) 2015-08-21 2019-01-10 Acerta Pharma B.V. Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
AU2018319344B2 (en) 2017-08-23 2024-04-04 Cell Receptor AG Combination of a MAPK/ERK pathway inhibitor and a glycosaminoglycan for the treatment of cancer
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
MX2023006434A (es) * 2020-12-16 2023-06-13 Abm Therapeutics Corp Inhibidores de quinasa y usos de los mismos.
EP4346826A4 (en) 2021-05-27 2025-04-30 Mirati Therapeutics, Inc. COMBINATION THERAPIES
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
WO2025147497A1 (en) 2024-01-05 2025-07-10 Pasithea Therapeutics Corp. Solid forms comprising (5r,6s)-10,11-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-1h-spiro[benzo[b][1,5,4]oxathiazecine-3,1'-cyclopropane] 2,2-dioxide, and compositions comprising and methods of using the same
WO2025147503A1 (en) 2024-01-05 2025-07-10 Pasithea Therapeutics Corp. 10,11-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-1h-spiro[benzo[b][1,5,4]oxathiazecine-3,1'-cyclopropane] 2,2-dioxide stereoisomers, and compositions comprising and methods of using the same

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
DK0821671T3 (da) 1995-04-20 2001-04-23 Pfizer Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer
DE69624081T2 (de) 1995-12-20 2003-06-12 Agouron Pharmaceuticals, Inc. Matrix-metalloprotease Inhibitoren
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
EP0923585B1 (en) 1996-07-18 2002-05-08 Pfizer Inc. Phosphinate based inhibitors of matrix metalloproteases
WO1998007697A1 (en) 1996-08-23 1998-02-26 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
WO1998030566A1 (en) 1997-01-06 1998-07-16 Pfizer Inc. Cyclic sulfone derivatives
EP0977733B1 (en) 1997-02-03 2003-09-03 Pfizer Products Inc. Arylsulfonylamino hydroxamic acid derivatives
JP2000507975A (ja) 1997-02-07 2000-06-27 ファイザー・インク Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
EA002546B1 (ru) 1997-02-11 2002-06-27 Пфайзер Инк. Производные арилсульфонилгидроксамовой кислоты
AU730248B2 (en) 1997-08-08 2001-03-01 Pfizer Products Inc. Aryloxyarylsulfonylamino hydroxamic acid derivatives
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
DK1004578T3 (da) 1998-11-05 2004-06-28 Pfizer Prod Inc 5-oxo-pyrrolidin-2-carboxylsyrehydroxamidderivater
GB9912961D0 (en) 1999-06-03 1999-08-04 Pfizer Ltd Metalloprotease inhibitors
GB0131034D0 (en) * 2001-12-28 2002-02-13 Pharmacia & Upjohn Spa Benzocyclodecane derivatives with antitumor activity
EP1467968A1 (en) * 2002-01-23 2004-10-20 Warner-Lambert Company LLC N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
MY144232A (en) * 2004-07-26 2011-08-15 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
US7429667B2 (en) 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
MX2008002114A (es) * 2005-07-21 2008-04-17 Ardea Biosciences Inc Inhibidores de n-(arilamino)-sulfonamida de mek.
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
SI1912636T1 (sl) 2005-07-21 2014-08-29 Ardea Biosciences, Inc. N-(arilamino)-sulfonamidni inhibitorji MEK
WO2009018233A1 (en) 2007-07-30 2009-02-05 Ardea Biosciences, Inc. Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same
US7842836B2 (en) 2006-04-11 2010-11-30 Ardea Biosciences N-aryl-N'alkyl sulfamides as MEK inhibitors
MX2008013097A (es) 2006-04-18 2008-10-27 Ardea Biosciences Inc Piridona sulfonamidas y piridona sulfamidas como inhibidores de metiletilcetona.
MX2009007661A (es) 2007-01-19 2009-12-14 Ardea Biosciences Inc Inhibidores de mek.
UA99731C2 (ru) 2007-07-30 2012-09-25 Ардеа Биосайенсис, Инк Кристаллические полиморфные формы n-(ариламино)сульфонамидов как ингибиторы мэк, композиция (варианты) и применение
CA2696977C (en) 2007-10-16 2012-12-04 Pharmathen S.A. Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof
US8044240B2 (en) 2008-03-06 2011-10-25 Ardea Biosciences Inc. Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof
US8808742B2 (en) * 2008-04-14 2014-08-19 Ardea Biosciences, Inc. Compositions and methods for preparing and using same
CN102134218A (zh) 2009-06-15 2011-07-27 凯美隆(北京)药业技术有限公司 6-芳氨基吡啶酮磺酰胺和6-芳氨基吡嗪酮磺酰胺mek抑制剂

Also Published As

Publication number Publication date
AU2010306830C1 (en) 2015-05-28
AU2010306830A1 (en) 2012-05-31
WO2011047055A2 (en) 2011-04-21
US9034861B2 (en) 2015-05-19
JP2013507453A (ja) 2013-03-04
ES2534358T3 (es) 2015-04-21
CN102666512A (zh) 2012-09-12
WO2011047055A3 (en) 2011-08-18
EP2488507A4 (en) 2013-05-01
EP2488507B1 (en) 2014-12-17
BR112012008599A2 (pt) 2019-09-24
KR20120094165A (ko) 2012-08-23
EP2488507A2 (en) 2012-08-22
AU2010306830B2 (en) 2014-11-06
WO2011047055A8 (en) 2012-05-24
CA2814617A1 (en) 2011-04-21
CA2814617C (en) 2017-12-19
CN102666512B (zh) 2014-11-26
US20120208859A1 (en) 2012-08-16

Similar Documents

Publication Publication Date Title
JP5892612B2 (ja) 疾患の処置に有用な新規のｍｅｋ阻害剤
ES2354182T3 (es) Piridona sulfonamidas y piridona sulfamidas como inhibidores de mek.
ES2543608T3 (es) Dihidropiridin sulfonamidas y dihidropiridin sulfamidas como inhibidores de MEK
US7842836B2 (en) N-aryl-N'alkyl sulfamides as MEK inhibitors
NZ582929A (en) Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same
JP2013545750A (ja) Ｎａｍｐｔ阻害剤
US20150250762A1 (en) Novel mek inhibitors for treating cardiomyopathies and related conditions
HK1174619A (en) Novel mek inhibitors, useful in the treatment of diseases
HK1128617B (en) Pyridone sulfonamides and pyridone sulfamides as mek inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131010

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131010

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140924

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150721

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160218

R150 Certificate of patent or registration of utility model

Ref document number: 5892612

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250